In women with relapsing-remitting MS, a six-month gluten-free diet was found to ease disability and support a healthier body ...

FDA has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent, to treat people with ...

Thousands of Australians battling a debilitating form of multiple sclerosis have been granted a reprieve, as a groundbreaking ...

With a new edition of a long-running awareness campaign, Genentech is drawing attention to the talents and passions that are ...

Cladribine is linked to lower risk for disability progression in patients with relapsing-remitting multiple sclerosis vs S1PRMs, at least in the short term, a study shows.

A dramatic price plunge has put a world-class therapy within reach, offering new freedom and hope for thousands of Australians.

Lupin has received tentative USFDA approval to market generic Siponimod Tablets for treating multiple sclerosis, strengthening its US portfolio in speciality medicines.

On October 30, 2025, in Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., Nos. 2025-1210, 2025-1211, the US Court of Appeals for the ...

Hydrotherapy significantly improved balance and reduced fatigue in MS patients compared to standard physiotherapy, enhancing daily function and energy levels. The study used the Modified Fatigue ...

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.

Contineum Therapeutics Inc.’s midstage study of its multiple sclerosis drug, PIPE-307, missed its primary and secondary endpoints, dropping the stock on Nov. 21. Top-line phase II results from the ...